Principal Consultant: Leads IND-enabling programs and preclinical strategy across gene therapy, oncology, and rare disease. Oversees CRO partnerships and regulatory documentation.
Head of DMPK/Analytical Sciences: Directed PK and ADME studies for nanoparticle therapeutics and led global clinical collaborations.
Head of DMPK: Managed a 20+ person team supporting small molecule and biologics programs. Drove IND transitions and global automation efforts.